Literature DB >> 8396080

In-vitro concentration of azithromycin in human phagocytic cells.

G Panteix1, B Guillaumond, R Harf, A Desbos, V Sapin, M Leclercq, M Perrin-Fayolle.   

Abstract

The in-vitro intraphagocytic uptake and retention of azithromycin in both human polymorphonuclear leucocytes (PMN) and alveolar macrophages was measured by an improved high-performance liquid chromatography (HPLC) method that was approximately three-fold more sensitive than previous methods. Azithromycin was accumulated in PMN and alveolar macrophages (about 300-fold), with maximum uptake being obtained after incubation for 60 min. Azithromycin was eliminated only partially from the cells during the washing process, and was released slowly during re-incubation of phagocytic cells in antibiotic-free medium. This intracellular retention distinguishes azithromycin from most of the macrolides and quinolones which, in spite of high I/E ratios, are released rapidly from cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396080     DOI: 10.1093/jac/31.suppl_e.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  Isolation of multidrug-resistant Salmonella in Singapore.

Authors:  Yee Wei Phoon; Yuen Yue Candice Chan; Tze Hsien Koh
Journal:  Singapore Med J       Date:  2015-08       Impact factor: 1.858

Review 2.  Non-surgical periodontal therapy supplemented with systemically administered azithromycin: a systematic review of RCTs.

Authors:  Sabrina L Buset; Nicola U Zitzmann; Roland Weiger; Clemens Walter
Journal:  Clin Oral Investig       Date:  2015-06-12       Impact factor: 3.573

3.  Azithromycin impact on neutrophil oxidative metabolism depends on exposure time.

Authors:  H Levert; B Gressier; I Moutard; C Brunet; T Dine; M Luyckx; M Cazin; J C Cazin
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

4.  A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.

Authors:  N T Chinh; C M Parry; N T Ly; H D Ha; M X Thong; T S Diep; J Wain; N J White; J J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.

Authors:  C Miossec-Bartoli; L Pilatre; P Peyron; E N N'Diaye; V Collart-Dutilleul; I Maridonneau-Parini; A Diu-Hercend
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.

Authors:  Christopher M Parry; Vo Anh Ho; Le Thi Phuong; Phan Van Be Bay; Mai Ngoc Lanh; Le Thanh Tung; Nguyen Thi Hong Tham; John Wain; Tran Tinh Hien; Jeremy J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

7.  Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.

Authors:  K B Patel; D Xuan; P R Tessier; J H Russomanno; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  V Berry; C E Thorburn; S J Knott; G Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Intracellular activity of azithromycin against bacterial enteric pathogens.

Authors:  R M Rakita; K Jacques-Palaz; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.